What is the efficacy of early treatment of choroidal melanoma?

Updated: Feb 18, 2020
  • Author: Enrique Garcia-Valenzuela, MD, PhD; Chief Editor: Andrew A Dahl, MD, FACS  more...
  • Print


In a prospective cohort study of 3072 patients with choroidal melanoma, researchers found that, for some patients, early treatment, rather than watchful waiting, might better prevent metastatic death. [7, 8]

For the study, researchers correlated age at death, cause of death, age at treatment, and survival predictors. Tumors ranged in size from 2.4 to 23.8 mm in basal diameter and from 0.6 to 18.3 mm in thickness, and the largest basal diameter correlated with all survival predictors except chromosome 6p gain. Older age at treatment was correlated with largest basal tumor diameter, tumor thickness, TNM stage, ciliary body involvement, extraocular spread, chromosome 3 loss, and chromosome 8q gain. A total of 1005 patients died by the end of the study, and 561 of these patients died from metastatic disease from uveal melanoma. Median age at death was lower (68.6 years) for patients who died from metastatic melanoma than for patients who died from any cause (74.0 years). None of the survival predictors correlated with age at death among the patients who died of metastasis except for mitotic count, which had a weak correlation. [7, 8]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!